These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 8508355)

  • 1. Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group.
    Ohno R; Kobayashi T; Tanimoto M; Hiraoka A; Imai K; Asou N; Tomonaga M; Tsubaki K; Takahashi I; Kodera Y
    Cancer; 1993 Jun; 71(12):3888-95. PubMed ID: 8508355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized study of individualized induction therapy with or without VCR, and of maintenance of 4 or 12 courses in adult AML: JALSG-AML87. Japan Adult Leukemia Study Group (JALSG).
    Ohno R; Kobayashi T; Morishima Y; Hiraoka A; Imai K; Asoh N; Tsubaki K; Tomonaga M; Takahashi I; Kodera K
    Leukemia; 1992; 6 Suppl 2():92-5. PubMed ID: 1578954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group.
    Kobayashi T; Miyawaki S; Tanimoto M; Kuriyama K; Murakami H; Yoshida M; Minami S; Minato K; Tsubaki K; Ohmoto E; Oh H; Jinnai I; Sakamaki H; Hiraoka A; Kanamaru A; Takahashi I; Saito K; Naoe T; Yamada O; Asou N; Kageyama S; Emi N; Matsuoka A; Tomonaga M; Ohno R
    J Clin Oncol; 1996 Jan; 14(1):204-13. PubMed ID: 8558199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group.
    Miyawaki S; Tanimoto M; Kobayashi T; Minami S; Tamura J; Omoto E; Kuriyama K; Hatake K; Saito K; Kanamaru A; Oh H; Ohtake S; Asou N; Sakamaki H; Yamada O; Jinnai I; Tsubaki K; Takeyama K; Hiraoka A; Matsuda S; Takahashi M; Shimazaki C; Adachi K; Kageyama S; Ohno R
    Int J Hematol; 1999 Aug; 70(2):97-104. PubMed ID: 10497848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
    Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of etoposide added to individualized induction therapy of adult acute myeloid leukemia--the JALSG-AML-92 Study. Japan Adult Leukemia Study Group].
    Miyawaki S; Tanimoto M; Kobayashi T; Minami S; Tamura J; Omoto E; Kuriyama K; Hatake K; Saito K; Ohno R
    Gan To Kagaku Ryoho; 2000 Jul; 27(8):1160-7. PubMed ID: 10945011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
    Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
    J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive individualized induction therapy with behenoyl cytarabine, daunorubicin and 6-mercaptopurine followed by intensive consolidation including intermediate-dose continuous cytarabine, mitoxantron, etoposide and vinca alkaloids in acute myeloid leukemia in adults.
    Ohno R; Yokomaku S; Okumura M; Nagai T; Kitaori K; Ito T; Takeo T; Sugiura I; Yano K; Ito Y
    Int J Hematol; 1991 Dec; 54(6):487-93. PubMed ID: 1793832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response-oriented individualized induction therapy followed by intensive consolidation and maintenance for adult patients with acute lymphoblastic leukemia: the ALL-87 study of the Japan Adult Leukemia Study Group (JALSG).
    Tanimoto M; Miyawaki S; Ino T; Kyo T; Sakamaki H; Naoe T; Hiraoka A; Asou N; Ohshima T; Tsubaki K; Kuriyama K; Ueda T; Minamil S; Okabe K; Saito H; Murakami H; Hirano M; Dohy H; Onozawa Y; Suzuki H; Ohno R
    Int J Hematol; 1998 Dec; 68(4):421-9. PubMed ID: 9885441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B.
    Ellison RR; Mick R; Cuttner J; Schiffer CA; Silver RT; Henderson ES; Woliver T; Royston I; Davey FR; Glicksman AS
    J Clin Oncol; 1991 Nov; 9(11):2002-15. PubMed ID: 1941059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.
    Weick JK; Kopecky KJ; Appelbaum FR; Head DR; Kingsbury LL; Balcerzak SP; Bickers JN; Hynes HE; Welborn JL; Simon SR; Grever M
    Blood; 1996 Oct; 88(8):2841-51. PubMed ID: 8874180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group.
    Jehn U; Zittoun R; Suciu S; Fiere D; Haanen C; Peetermans M; Löwenberg B; Willemze R; Solbu G; Stryckmans P
    Haematol Blood Transfus; 1990; 33():277-84. PubMed ID: 1691132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study.
    Takeuchi J; Kyo T; Naito K; Sao H; Takahashi M; Miyawaki S; Kuriyama K; Ohtake S; Yagasaki F; Murakami H; Asou N; Ino T; Okamoto T; Usui N; Nishimura M; Shinagawa K; Fukushima T; Taguchi H; Morii T; Mizuta S; Akiyama H; Nakamura Y; Ohshima T; Ohno R
    Leukemia; 2002 Jul; 16(7):1259-66. PubMed ID: 12094249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study. MRC Leukaemia in Adults Working Party.
    Rees JK; Gray RG; Wheatley K
    Br J Haematol; 1996 Jul; 94(1):89-98. PubMed ID: 8757514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of postremission chemotherapy for adults with acute myeloid leukemia using different dose-intensities.
    Jehn U
    Leuk Lymphoma; 1994 Sep; 15(1-2):99-112. PubMed ID: 7532060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia. A Leukemia-Lymphoma Group Trial of the EORTC.
    Hayat M; Jehn U; Willemze R; Haanen C; Zittoun R; Monconduit M; Lowenberg B; Stryckmans P; Peetermans M; De Cataldo F
    Cancer; 1986 Aug; 58(3):617-23. PubMed ID: 3524789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.
    Fukushima T; Urasaki Y; Yamaguchi M; Ueda M; Morinaga K; Haba T; Sugiyama T; Nakao S; Origasa H; Umehara H; Ueda T
    Anticancer Res; 2012 Feb; 32(2):643-7. PubMed ID: 22287757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nationwide randomized comparative study of daunorubicin and aclarubicin in combination with behenoyl cytosine arabinoside, 6-mercaptopurine, and prednisolone for previously untreated acute myeloid leukemia.
    Nagura E; Kimura K; Yamada K; Ohta K; Maekawa T; Takaku F; Uchino H; Masaoka T; Amaki I; Kawashima K
    Cancer Chemother Pharmacol; 1994; 34(1):23-9. PubMed ID: 8174198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. All-trans retinoic acid therapy for newly diagnosed acute promyelocytic leukemia: comparison with intensive chemotherapy. The Japan Adult Leukemia Study Group (JALSG).
    Asou N; Adachi K; Tamura J; Kanamaru A; Kageyama S; Hiraoka A; Omoto E; Sakamaki H; Tsubaki K; Saito K; Ohno R
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S30-5. PubMed ID: 9272131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: the ALL90 study of the Japan Adult Leukemia Study Group.
    Ueda T; Miyawaki S; Asou N; Kuraishi Y; Hiraoka A; Kuriyama K; Minami S; Ohshima T; Ino T; Tamura J; Kanamaru A; Nishikawa K; Tanimoto M; Oh H; Saito K; Nagata K; Naoe T; Yamada O; Urasaki Y; Sakura T; Ohno R
    Int J Hematol; 1998 Oct; 68(3):279-89. PubMed ID: 9846012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.